Department of Internal Medicine I, University Medical Center Regensburg, Franz-Josef-Strauss-Allee 11, 93042 Regensburg, Germany.
Immunotherapy. 2010 Jul;2(4):539-50. doi: 10.2217/imt.10.26.
At present, the treatment of T-cell-dependent autoimmune diseases relies exclusively on strategies leading to nonspecific suppression of the immune systems causing a substantial reduced ability to control concomitant infections or malignancies. Furthermore, long-term treatment with most drugs is accompanied by several serious adverse effects and does not consequently result in cure of the primary immunological malfunction. By contrast, antigen-specific immunotherapy offers the potential to achieve the highest therapeutic efficiency in accordance with minimal adverse effects. Therefore, several studies have been performed utilizing antigen-presenting cells specifically engineered to deplete allo- or antigen-specific T cells ('guided missiles'). Many of these strategies take advantage of the Fas/Fas ligand signaling pathway to efficiently induce antigen-presenting cell-mediated apoptosis in targeted T cells. In this article, we discuss the advantages and shortcomings of a novel non-cell-based 'killer artificial antigen-presenting cell' strategy, developed to overcome obstacles related to current cell-based approaches for the treatment of T-cell-mediated autoimmunity.
目前，T 细胞依赖性自身免疫性疾病的治疗完全依赖于导致免疫系统非特异性抑制的策略，这会导致对伴随感染或恶性肿瘤的控制能力显著降低。此外，大多数药物的长期治疗伴随着多种严重的不良反应，并且不会导致原发性免疫功能障碍的治愈。相比之下，抗原特异性免疫疗法具有在最小不良反应的情况下实现最高治疗效率的潜力。因此，已经进行了几项研究，利用专门设计用于耗尽同种异体或抗原特异性 T 细胞的抗原呈递细胞（“制导导弹”）。这些策略中的许多利用 Fas/Fas 配体信号通路来有效地诱导靶向 T 细胞中的抗原呈递细胞介导的细胞凋亡。在本文中，我们讨论了一种新型非细胞基“杀伤性人工抗原呈递细胞”策略的优缺点，该策略旨在克服与目前基于细胞的 T 细胞介导自身免疫治疗方法相关的障碍。
